Clinical Trials
24 trialsDIRECT
University Health Network, Toronto
Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer
University of Wisconsin, Madison
ARPEGGIO
Brigham and Women's Hospital
Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors
Dana-Farber Cancer Institute
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
M.D. Anderson Cancer Center
EVOLVE-BDT
UNC Lineberger Comprehensive Cancer Center
RADVAN
Sun Yat-sen University
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
M.D. Anderson Cancer Center
Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC
H. Lee Moffitt Cancer Center and Research Institute
TRAP
Royal Marsden NHS Foundation Trust
KNIGHTS
University of Maryland, Baltimore
Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer
Washington University School of Medicine
GETUG-AFU 40
UNICANCER
Prostate005
University of Virginia
Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer
University of Nebraska
HARMONY
Hoosier Cancer Research Network
Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy
H. Lee Moffitt Cancer Center and Research Institute
FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial
Northwestern University
OMPC-RPM
Fudan University
PRO-BOOST-LC
Affidea Nu-med Center of Oncological DIagnostics and Therapy
PRO-BOOST-N
Affidea Nu-med Center of Oncological DIagnostics and Therapy
HYP-OP-RT
CHU de Quebec-Universite Laval
PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.
First Affiliated Hospital of Wenzhou Medical University
ANDARP
Cancer Institute and Hospital, Chinese Academy of Medical Sciences